WO2024147074 - METHODS FOR TREATING POTS USING FCRN ANTAGONISTS
National phase entry is expected:
Publication Number
WO/2024/147074
Publication Date
11.07.2024
International Application No.
PCT/IB2024/000018
International Filing Date
05.01.2024
Title **
[English]
METHODS FOR TREATING POTS USING FCRN ANTAGONISTS
[French]
PROCÉDÉS DE TRAITEMENT DU STOP À L'AIDE D'ANTAGONISTES DE FCRN
Applicants **
ARGENX BV
Inventors
VAN MIDDENDORP, Joost, Johannes
CHUNG, Tae, Hwan
Priority Data
63/437,552
06.01.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2316 | |
| EPO | Filing, Examination, Granting | 9948 | |
| Japan | Filing, Examination, Granting | 2043 | |
| South Korea | Filing, Examination, Granting | 1722 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
20,769
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Provided herein are methods of treating postural orthostatic tachycardia syndrome (POTS) using an effective amount of a human neonatal Fc receptor (FcRn) antagonist. FcRn antagonists for use in the treatment of POTS and for use in the manufacture of a medicament for the treatment of POTS are also provided herein.[French]
L'invention concerne des méthodes de traitement du syndrome de tachycardie orthostatique posturale (STOP) à l'aide d'une quantité efficace d'un antagoniste du récepteur Fc néonatal humain (FcRn). L'invention concerne également des antagonistes de FcRn destinés à être utilisés dans le traitement du STOP et destinés à être utilisés dans la fabrication d'un médicament pour le traitement du STOP.